Sinovac Biotech Ltd (SVA): Long-Term Debt
$494.86M
As of 2025-12-31
+247.4%
3-year compound annual growth
+69.8%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $494.86M | +31.7% | 2026-06-05, Balance as of period end |
| 2024-12-31 | $375.76M | +48.0% | 2026-04-30, Balance as of period end |
| 2023-12-31 | $253.91M | n/m | 2024-04-29, Balance as of period end |
| 2022-12-31 | $11.81M | -25.1% | 2023-05-01, Balance as of period end |
| 2021-12-31 | $15.77M | -55.1% | 2022-04-29, Balance as of period end |
| 2020-12-31 | $35.10M | +491.4% | 2021-04-22, Balance as of period end |
| 2019-12-31 | $5.93M | -17.7% | 2020-04-30, Balance as of period end |
| 2018-12-31 | $7.21M | -78.1% | 2019-04-29, Balance as of period end |
| 2017-12-31 | $33.00M | -19.0% | 2018-05-11, Balance as of period end |
| 2016-12-31 | $40.73M | n/a | 2017-11-22, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $494.86M | +31.7% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $2.01B | n/a |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $93.16M | +12.5% |
Compare SVA, ARQT, ARDX, MNKD side by side · Screen every company in Pharmaceutical Preparations ↗